Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Decreases Stock Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lessened its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 5.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,460 shares of the company’s stock after selling 140 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in GE HealthCare Technologies were worth $192,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Park Avenue Securities LLC raised its position in GE HealthCare Technologies by 38.8% in the third quarter. Park Avenue Securities LLC now owns 4,058 shares of the company’s stock valued at $381,000 after purchasing an additional 1,135 shares during the period. CWM LLC raised its holdings in shares of GE HealthCare Technologies by 5.0% during the 3rd quarter. CWM LLC now owns 11,186 shares of the company’s stock valued at $1,050,000 after buying an additional 531 shares during the period. UMB Bank n.a. lifted its position in GE HealthCare Technologies by 34.2% during the 3rd quarter. UMB Bank n.a. now owns 2,058 shares of the company’s stock worth $193,000 after acquiring an additional 524 shares in the last quarter. Clarius Group LLC purchased a new position in GE HealthCare Technologies in the 3rd quarter worth approximately $229,000. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its position in GE HealthCare Technologies by 587.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 3,160 shares of the company’s stock valued at $296,000 after acquiring an additional 2,700 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on GEHC. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their target price for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. Wells Fargo & Company boosted their price objective on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, GE HealthCare Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $96.00.

GE HealthCare Technologies Stock Down 1.0 %

Shares of GE HealthCare Technologies stock opened at $87.64 on Monday. The company has a quick ratio of 0.98, a current ratio of 1.23 and a debt-to-equity ratio of 1.12. The business has a 50-day moving average price of $83.34 and a 200 day moving average price of $85.28. GE HealthCare Technologies Inc. has a fifty-two week low of $74.51 and a fifty-two week high of $94.55. The firm has a market cap of $40.04 billion, a P/E ratio of 24.08, a P/E/G ratio of 2.93 and a beta of 1.15.

GE HealthCare Technologies Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be given a dividend of $0.035 per share. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. This represents a $0.14 annualized dividend and a dividend yield of 0.16%. The ex-dividend date is Tuesday, January 14th. GE HealthCare Technologies’s dividend payout ratio is currently 3.85%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.